About Zepteon
Zepteon is a Healthcare company based in Boston (United States) founded in 2012. Biomolecular separation tools for antibody potency evaluation are developed. Zepteon has raised $210 thousand across 1 funding round. Zepteon offers products and services including Glycap-3A. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Reagents and Kits and Biologics Purification. Its legal entity is Zepteon, Inc. Its competitors include Isolere Bio, VIRAPUR and GenTegra; 1 of its 3 listed competitors has raised funding.
Company details
Founded in 2012 and based in Boston, United States, Zepteon operates in the biopharmaceutical sector. Technology focused on antibody development and manufacturing is provided through Glycap-3A chromatography resin, which separates high-potency antibodies from mixtures. This approach supports drug potency tuning, regulatory structure-function characterization, and production of biosimilars, biobetters, and novel therapeutics. Services are extended to monoclonal antibody and plasma-derived antibody markets via fees, milestones, and royalties.
- Headquarters Boston, United States
- SectorsHealthcare
- Website zepteon.com
- Social LinkedIn
- Legal Name Zepteon, Inc
- Total Equity Funding$210K (USD)
in 1 rounds
- Latest Funding Round$210K (USD), Seed
Apr 2015
Products & Services of Zepteon
Zepteon offers a comprehensive portfolio of products and services, including Glycap-3A.
Separates nonfucosylated or bisected IgG glycoforms for enhanced antibody production.
Funding Insights of Zepteon
Zepteon has successfully raised a total of $210K through 1 strategic funding round. The most recent funding activity was a Seed round of $210 thousand completed in April 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $210,000
- Total Rounds 1
- Last Round Seed — $210,000
- First Round $210,000
(Apr 2015)
All 1 funding rounds of Zepteon with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2015 | $210,000 | Seed | – | – | – |
People of Zepteon
6 people are tracked at Zepteon (2 in leadership, 4 in board & advisors).
| Name | Role | Group |
|---|---|---|
Glen R. Bolton | COO & Co-founder | Leadership |
Austin W. Boesch | CEO & co-founder | Leadership |
Ronald Sia | Advisor | Board & advisors |
Marc Silver | Advisor | Board & advisors |
Maria Grunwald | Advisor | Board & advisors |
Tom Ransohoff | Advisor | Board & advisors |
Complete people profiles for Zepteon
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Zepteon
2 dated milestones of Zepteon across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Zepteon is founded.
- Funding First funding round of $210K.
Competitors of Zepteon
Zepteon has 3 listed competitors in our database, 1 of them funded. They include Isolere Bio, VIRAPUR and GenTegra.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| isolerebio.com | 2017 | Durham, United States | $7M | A platform for biotherapeutics purification is provided using TFF technology. | ||
| virapur.com | 2000 | San Diego, United States | Provides viral reagents and assay services for scientific and medical research. | |||
| gentegra.com | 2013 | Pleasanton, United States | Nucleic acid stabilization products are developed by GenTegra. |
Detailed competitors of Zepteon
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Zepteon (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Zepteon
Zepteon was founded in 2012 and raised its 1st funding round 3 years after it was founded.
Zepteon is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Zepteon is a funded company, having raised a total of $210K across 1 funding round to date. The company's 1st funding round was a Seed of $210K, raised on Apr 2015.
Founded in 2012 and based in Boston, United States, Zepteon operates in the biopharmaceutical sector. Technology focused on antibody development and manufacturing is provided through Glycap-3A chromatography resin, which separates high-potency antibodies from mixtures. This approach supports drug potency tuning, regulatory structure-function characterization, and production of biosimilars, biobetters, and novel therapeutics. Services are extended to monoclonal antibody and plasma-derived antibody markets via fees, milestones, and royalties.
Zepteon's top competitors include Isolere Bio, GenTegra and VIRAPUR.
Zepteon offers Glycap-3A.
Zepteon operates through Zepteon, Inc.